Thymosin Alpha-1 (TA-1) is a powerful immune-modulating peptide originally derived from the thymus gland. Today it is produced synthetically and widely used to restore immune balance, enhance resistance to infections, and support cancer and chronic disease therapies. Under the trade name Zadaxin, TA-1 has received FDA orphan drug approval and is considered a breakthrough in immune-based treatments.
How It Works
TA-1 strengthens the body’s natural defense by targeting the T-cell system — the backbone of cellular immunity. It promotes the development of new T-cells, protects them from premature cell death, and activates dendritic cells to improve immune surveillance. By regulating cytokine and chemokine activity, TA-1 boosts the immune system’s ability to fight off infections, control inflammation, and recognise abnormal or cancerous cells.
Core mechanisms include:
- T-cell activation and differentiation – improves pathogen and cancer recognition.
- Dendritic cell stimulation – enhances immune alertness and response speed.
- Cytokine regulation – balances inflammation and coordinates immune activity.
- Anti-apoptotic effect – protects developing immune cells from stress and steroids.
Key Benefits
- Anti-Cancer Support: Works alongside chemotherapy, radiotherapy, and immunotherapy by priming the immune system to better detect and destroy tumour cells.
- Anti-Viral Action: Strengthens immune defence against viruses including hepatitis B, hepatitis C, and other emerging infections.
- Immune Balance: Helps regulate immune function in autoimmune conditions, chronic fatigue, Lyme disease, and immune deficiencies.
- Gene Therapy Potential: Early research shows TA-1 can influence immune-related gene expression, offering promise in precision medicine.
- Well-Tolerated: Minimal side effects, making it a safe option for long-term immune support.
Clinical Applications
- Oncology (melanoma, lung, liver, and blood cancers)
- Chronic viral infections (HBV, HCV, emerging viral diseases)
- Autoimmune and chronic immune conditions
- Supportive therapy in chronic fatigue and immune dysregulation
Molecular Profile
- Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu
- Length: 28 amino acids
- CAS Number: 62304-98-7
Dosage & Administration
- Subcutaneous injection is the most common route.
- Typical clinical dosing ranges from 1.6 mg – 3.2 mg, administered two to three times per week, depending on indication.
- Storage: Keep frozen until first use. After reconstitution, refrigerate at 2–8 °C for up to 42 days.
Safety
TA-1 is well-tolerated with a strong safety record. Mild side effects may include redness at the injection site, temporary fatigue, or flu-like symptoms.
Summary
Thymosin Alpha-1 is a next-generation peptide for immune balance, viral defence, and cancer support. By enhancing T-cell function and regulating cytokine responses, it helps the body restore natural immunity and protect against disease. With decades of clinical use and ongoing research in oncology, virology, and gene therapy, TA-1 stands as one of the most versatile and promising immune-modulating therapies available.